Presence of FOXP3+ Treg cells is correlated with colorectal cancer progression

International Journal of Clinical and Experimental Medicine

Volumn 7, Issue 7, 2014, Pages 1781-1785

  Liu, Zhengcai ^a   Huang, Qike ^a   Liu, Guangxin ^a   Dang, Lili ^a   Chu, Dake ^a   Tao, Kaishan ^a   Wang, Weizhong ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Colorectal cancer; Flow cytometry; Fork head winged helix transcription factor 3; Immunohistochemistry; Regulatory T cells

Indexed keywords

EID: 84905665488     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008, cancer incidence and mortality worldwide: IARC cancerbase No.10. Lyon: International Agency for Research on Cancer; 2010.
2. Littman DR, Rudensky A. Th17 and regulatory T Cells in mediating and restraining inflammation. Cell 2010; 140: 845-58.
3. Brunkow ME, Jeffery EW, Hjerrild KA, Paeper B, Clark LB, Yasayko SA, Wilkinson JE, Galas D, Ziegler SF, Ramsdell F. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 2001; 27: 68-73.
4. Marzano AV, Vezzoli P, Fanoni D, Venegoni L, Berti E. Primary cutaneous T-cell lymphoma expressing FoxP3: a case report supporting the existence of malignancies of regulatory T cells. J Am Acad Dermatol 2009; 61: 348-355.
5. Ye J, Ma C, Wang F, Hsueh EC, Toth K, Huang Y, Mo W, Liu S, Han B, Varvares MA, Hoft DF, Peng G. Specific recruitmentof γδ regulatory T cells in human breast cancer. Cancer 2013; 6: 855-859.
6. Beyer M, Schultze JL. Regulatory T cells in cancer. Blood 2006; 108: 804-11.
7. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell 2008; 133: 775-87.
8. + T cells. Blood 2007; 109: 2058-2065.
9. Kim M, Grimmig T, Grimm M, et al. Expression of Foxp3 in colorectal cancer but not in Treg cells correlates with disease progression in patients with colorectal cancer. PLoS One 2013; 8: 53-63.
10. Takeuchi H, Kitajima M, Kitagawa Y. Sentinel lymph node as a target of molecular diagnosis of lymphatic micrometastasis and local immunoresponse to malignant cells. Cancer Sci 2008; 99: 441-450.
11. + regulatory T-cell density in the sentinel lymph node is associated with downstream non-sentinel lymph-node metastasis in gastric cancer. Br J Cancer 2011; 105: 413-419.
12. Weber J. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010). Oncologist 2008; 13: 16-25.
13. + regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels. Cancer Res 2010; 70: 4850-4858.
14. Medina-Echeverz J, Fioravanti J, Zabala M, Ardaiz N, Prieto J, Berraondo P. Successful colon cancer eradication after chemoimmunotherapy is associated with profound phenotypic change of intratumoral myeloid cells. Immunol 2011; 186: 807-815.
15. Morse MA, Hobeika AC, Osada T, Serra D, Niedzwiecki D, Lyerly HK, Clay TM. Depletion of humanregulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood 2008; 112: 610-618.
16. Jacobs JF, Punt CJ, Lesterhuis WJ, Sutmuller RP, Brouwer HM, Scharenborg NM, Klasen IS, Hilbrands LB, Figdor CG, de Vries IJ, Adema GJ. Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a Phase I/II study in metastatic melanoma patients. Clin Cancer Res 2010; 16: 5067-5078.